Microsangrados silentes en pacientes con enfermedad cerebrovascular sintomática
PONZ A, CHAMARRO R, GIL R, SANTONJA J, LÁINEZ J
Neurología 2008;23(9): 587-592
Resumen del Autor:
Introduction. T2*-weighted gradient echo MRI sequences (T2*-MRI) have made it possible to detect cerebral microhemorrhages (MH) that have been considered as subclinical but whose clinical significance is largely unknown. Objective. To establish the frequency of MH in a sample of consecutive symptomatic cerebrovascular disease (SCD) patients, analyzing its associations with different vascular risk factors (VRF) and its clinical significance. Methods. A total of 198 patients with SCD were consecutively examined using T2*-MRI. Preferential location of MH and associations between MH presence and MH number with VRF, previous antithrombotic treatment and SCD subtypes were analyzed. Results. A total of 52.5% of our patients had MH. The highest frequency of MH was found in hemorrhagic strokes (72.2%), Transitoy ischemic attack (TIA) (42.9%) being the group with the lowest frequency. According to the bivariate analysis, the factors associated with the presence of MH were elderly age (72.4±10.5 vs 67.7±12.7; p 0.004), hypertension (65.4 vs 51.1%; p 0.041), diabetes (35.6 vs 22.3 %; p 0.041) and being under antithrombotic treatment (45.2 vs 28.7 %; p 0.017). According to the multivariate analysis, elderly age (p 0.019; OR: 1.03 [1.01- 1.06]), hypertension (p 0.032; OR: 1.97 [1.06-3.65]), use of antithrombotic treatment (p 0.038; OR: 1.95 [1.04-3.65]) and having a hemorrhagic stroke (p 0.028; OR: 3.63 [1.15- 11.46]) were predictors of MH presence. Conclusions. The presence of MH is frequent among patients with SCD, this being especially elevated in patients with hemorrhagic stroke. Cerebral MHs are classically associated with VRF classically related with small vessel disease and previously taking antithrombotic treatment. Key words: Cerebral microhemorrhages. Gradient echo. Neuroimaging. Neurología 2008;23(9):587-592
* RECUERDE. Al pulsar el enlace “Texto completo”, usted abandonará el entorno MEDES. En ese caso, la web a la que desea acceder no es propiedad de Fundación Lilly y, por tanto, ésta no se responsabiliza de los contenidos, informaciones o servicios presentes en ella, ni de la política de privacidad que aplique el sitio web de un tercero.